COVID-19 Enfeksiyonunda Konvalesan (İmmün) Plazma Kullanımı

Çin’de Wuhan eyaletinde Aralık 2019’da başlayan ve insanlarda ciddi solunum yolu enfeksiyonlarına neden olan Coronavirus 2 (SARS-CoV-2) çok hızlı bir yayılım göstererek 11 Mart 2020 tarihinde pandemi olarak kabul edilmiştir. SARS-CoV-2 kaynaklı hastalık tablosuna COVID-19 adı verilmektedir. Beş ay gibi kısa bir sürede yaklaşık 4 milyon kişi enfekte olmuş ve 300 bin kişi bu hastalıktan kaybedilmiştir. Günümüze kadar etkili bir profilaksi ve tedavisi bulunamayan hastalıkta iyileşen hastaların plazması ile pasif bağışıklama tedavi seçenekleri arasında bulunmaktadır. Konvalesan plazma tedavisi geçmişte salgın hastalık dönemlerinde kullanılmış, etkili olduğu gösterilmiştir. Plazmadaki nötralizan antikorlar virüsü inaktive ederek iyileşmeye katkı sağlamaktadır. Literatürde, konvalesan plazma verilen toplam 21 hastanın sunulduğu 4 yayın bulunmaktadır. Hastaların konvalesan plazma tedavisinden fayda gördüklerini ve herhangi bir komplikasyon olmadığını bildirmişlerdir. Tüm dünyada konvalesan plazmayla ilgili başlatılmış çalışmalar olup bunların sonuçları merakla beklenmektedir.

Use of Convalesant Plasma in CoOVID-19 Infection

Coronavirus 2 (SARS-CoV-2), which started in December 2019 in Wuhan province in China and caused seriousrespiratory infections in humans, was accepted as a pandemic on March 11, 2020. The disease from SARS-CoV-2 iscalled COVID-19. In a short period of five months, approximately 4 million people were infected and 300 thousand peopledied from this disease. To date, no specific therapeutic agents or prophylaxis for COVID-19 are available, so it is amongthe passive immunization treatment options with the plasma of patients who recover from the disease. Convalescentplasma therapy has been used in epidemic periods in the past and has been shown to be effective. Neutralizingantibodies in plasma contributes to recovery by inactivating the virus. In the literature, there are 4 publications presentinga total of 21 patients receiving convalescent plasma. They reported that the patients benefited from the treatment ofconvalescent plasma and that there were no complications. Studies have been initiated about convalescent plasma allover the world and their results are interestedly awaited.

PDF

___

1. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41:145-51.
2. Yin S, Peng Y, Ren Y, Hu M, Tang L, Xiang Z, et al. The implications of preliminary screening and diagnosis: Clinical characteristics of 33 mild patients with SARS-CoV-2 infection in Hunan, China. J Clin Virol 2020;128:104397.
3. Gasparyan AY, Misra DP, Yessirkepov M, Zimba O. Perspectives of Immune Therapy in Coronavirus Disease 2019. J Korean Med Sci 2020;35:e176.
4. Rojas M, Rodriguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev 2020;19:102554.
5. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 2020;26:453-5.
6. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. T J Clin Invest 2020;130:1545-8.
7. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. BMJ 2020;3:16. Doi: 10.1101/2020.03.16.20036145
8. Investigational covid-19 convalescent plasma—emergency INDs. https://www.fda. gov/ vaccines-blood-biologics/investigationalnewdrug-ind-or-device-exemption-ideprocesscber/ investigational-covid19-convalescent-plasma-emergency-inds
9. WHO. Rolling updates on corona virüs disease (COVID-19). https:// www.who.int/emergencies/diseases/novel-coronavirus-2019/ events-as-they-happen. Updated March 17, 2020 Accessed March 18, 2020.
10. Turkish Ministry of Health Immune Plasma Guidelines, 2020. Available from: URL: https://dosyamerkez.saglik.gov.tr/ Eklenti/37163,covid-19-immun-plazma-rehberi-12-nisan-2020 sonv1-ti-neopdfpdf.pdf?0&_tag1=D61DB6867EF68EE9A7FE73C 870D9BBA04AACC05C
11. McGonagle D, Sharif K, O’Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity rev 2020;19:102537.
12. COVID-19 and Convalescent Plasma: Frequently Asked Questions, ASH Webinar on the Use of Convalescent Plasma During COVID-19, hematology.zoom.us/webinar/register/WN_ iSKRIhdeSPe8YEuu0C37Vg 8 May, 2020.
13. Zhang B, Liu S, Tan T,Huang W, Dong Y, Chen L, et al. Treatment With Convalescent Plasma for Critically Ill Patients With SARSCoV-2 Infection. Chest 2020;S0012-3692(20)30571-7.
14. Liu BP, Chong EY, Cheung FW, Duan JA, Che CT, Liu WK. Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells. Biochem Pharmacol 2005;70:287-99.
15. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020;323:1582-9.
16. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Beak YJ, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci 2020 ;35:e149.